Summary
Nanoliposomes are good drug delivery systems that allow the encapsulation of drugs into vesicles for their delivery. The objective of this study is to investigate the therapeutic efficacy of a new radio-therapeutics of 188Re-labeled pegylated liposome in a C26 murine colon carcinoma solid tumor model. The safety of 188Re-liposome was evaluated before radiotherapy treatment. The anti-tumor effect of 188Re-liposome was assessed by tumor growth inhibition, survival ratio and ultrasound imaging. Apoptotic marker in tumor was also evaluated by the TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling) method after injection of 188Re-liposome. The group treated with 188Re-liposome displayed slight loss in body weight and decrease in white blood cell (WBC) count 7 to 14 days post-injection. With respect to therapeutic efficacy, the tumor-bearing mice treated with 188Re-liposome showed better mean tumor growth inhibition rate (MGI) and longer median survival time (MGI = 0.140; 80 day) than those treated with anti-cancer drug 5-FU (MGI = 0.195; 69 day) and untreated control mice (MGI = 0.413; 48 day). The ultrasound imaging showed a decrease in both tumor volume and number of blood vessels. There were significantly more apoptotic nuclei (TUNEL-positive) in 188Re-liposome-treated mice at 8 h after treatment than in control mice. These results evidenced the potential benefits achieved by oncological application of the radio-therapeutics 188Re-liposome for adjuvant cancer treatment.
Similar content being viewed by others
References
Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev 7:771–782
Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–1316
Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161–171
Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ (2007) Adjuvant treatment of colorectal cancer. CA Cancer J Clin 57:168–185
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939–944
Vincent M, Labianca R, Harper P (1999) Which 5-fluorouracil regimen?–the great debate. Anticancer Drugs 10:337–354
Yoshida M, Hoshi A, Kuretani K (1980) The difference in mechanism of action of 5-fluorouracil and its nucleosides in L5178y cells. J Pharmacobiodyn 3:374–379
Heidelberger C (1981) On the rational development of a new drug: the example of the fluorinated pyrimidines. Cancer Treat Rep 65(Suppl 3):3–9
Nahas A, Savlov ED, Hall TC (1974) Phosphoriboxyl transferase in colon tumor and normal mucosa as an aid in adjuvant chemotherapy with 5-fluorouracil (NSC-19893). Cancer Chemother Rep 58:909–912
Nadal JC, van Groeningen CJ, Pinedo HM, Peters GJ (1989) Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma. Invest New Drugs 7:163–172
Porschen R, Bermann A, Loffler T, Haack G, Rettig K, Anger Y, Strohmeyer G (2001) Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 19:1787–1794
Van Cutsem E, Peeters M (1999) Developments in fluoropyrimidine therapy for gastrointestinal cancer. Curr Opin Oncol 11:312–317
Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A (2001) Risk factors for male breast cancer–a case–control study from Scandinavia. Acta Oncol 40:467–471
O’Connell MJ (2004) Current status of adjuvant therapy for colorectal cancer. Oncology (Williston Park) 18:751–755, discussion 5–8
Chung KY, Saltz LB (2007) Adjuvant therapy of colon cancer: current status and future directions. Cancer J 13:192–197
Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659
Chang YJ, Chang CH, Chang TJ, Yu CY, Chen LC, Jan ML, Luo TY, Lee TW, Ting G (2007) Biodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 27:2217–2225
Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, Yeh CH, Luo TY, Lee TW, Ting G (2007) Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 34:415–423
Chen LC, Wu YH, Liu IH, Ho CL, Lee WC, Chang CH, Lan KL, Ting G, Lee TW, Shien JH (2012) Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. Nucl Med Biol 39:35–43
Tsai CC, Chang CH, Chen LC, Chang YJ, Lan KL, Wu YH, Hsu CW, Liu IH, Ho CL, Lee WC, Ni HC, Chang TJ et al (2012) Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. Int J Nanomedicine 6:2607–2619
McDonnell TJ, Meyn RE, Robertson LE (1995) Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 6:53–60
Bold RJ, Termuhlen PM, McConkey DJ (1997) Apoptosis, cancer and cancer therapy. Surg Oncol 6:133–142
Rosen EM, Vinter DW, Goldberg ID (1989) Hypertrophy of cultured bovine aortic endothelium following irradiation. Radiat Res 117:395–408
Dietz A, Delorme S, Rudat V, Zuna I, Conradt C, Vanselow B, Weidauer H (2000) Prognostic assessment of sonography and tumor volumetry in advanced cancer of the head and neck by use of doppler ultrasonography. Otolaryngol Head Neck Surg 122:596–601
Lassau N, Lamuraglia M, Vanel D, Le Cesne A, Chami L, Jaziri S, Terrier P, Roche A, Leclere J, Bonvalot S (2005) Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 16:1054–1060
Ogura O, Takebayashi Y, Sameshima T, Maeda S, Yamada K, Hata K, Akiba S, Aikou T (2001) Preoperative assessment of vascularity by color Doppler ultrasonography in human rectal carcinoma. Dis Colon Rectum 44:538–546, discussion 46–8
Bao A, Goins B, Klipper R, Negrete G, Phillips WT (2003) 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 44:1992–1999
Chen LC, Chang CH, Yu CY, Chang YJ, Wu YH, Lee WC, Yeh CH, Lee TW, Ting G (2008) Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of 188Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol 35:883–893
Chang YJ, Chang CH, Yu CY, Chang TJ, Chen LC, Chen MH, Lee TW, Ting G (2010) Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol 37:95–104
Carlsson G, Gullberg B, Hafstrom L (1983) Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 105:20–23
Fang F, Wang AP, Yang SF (2005) Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin 26:1373–1381
Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13:2795–2803
Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE (2009) 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med 50:2017–2024
de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK (2008) Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol 88:121–133
Zavaleta CL, Goins BA, Bao A, McManus LM, McMahan CA, Phillips WT (2008) Imaging of 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis. J Drug Target 16:626–637
Liu CM, Chang CH, Chang YJ, Hsu CW, Chen LC, Chen HL, Ho CL, Yu CY, Chang TJ, Chiang TC, Lee TW (2010) Preliminary evaluation of acute toxicity of 188Re-BMEDA-liposome in rats. J Appl Toxicol 30:680–687
De Ruyck K, Lambert B, Bacher K, Gemmel F, De Vos F, Vral A, de Ridder L, Dierckx RA, Thierens H (2004) Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma. J Nucl Med 45:612–618
Chen P, Cameron R, Wang J, Vallis KA, Reilly RM (2003) Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 44:1469–1478
Behr TM, Sgouros G, Stabin MG, Behe M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W (1999) Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin Cancer Res 5:3031s–3043s
Behr TM, Behe M, Sgouros G (2002) Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm 17:445–464
Hendry JH, Potten CS (1982) Intestinal cell radiosensitivity: a comparison for cell death assayed by apoptosis or by a loss of clonogenicity. Int J Radiat Biol Relat Stud Phys Chem Med 42:621–628
Potten CS (1992) The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metastasis Rev 11:179–195
Stephens LC, King GK, Peters LJ, Ang KK, Schultheiss TE, Jardine JH (1986) Unique radiosensitivity of serous cells in rhesus monkey submandibular glands. Am J Pathol 124:479–487
Stephens LC, Schultheiss TE, Small SM, Ang KK, Peters LJ (1989) Response of parotid gland organ culture to radiation. Radiat Res 120:140–153
Dewey WC, Ling CC, Meyn RE (1995) Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 33:781–796
Verheij M, Bartelink H (2000) Radiation-induced apoptosis. Cell Tissue Res 301:133–142
Jonathan EC, Bernhard EJ, McKenna WG (1999) How does radiation kill cells? Curr Opin Chem Biol 3:77–83
Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P (2007) Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 67:3970–3975
Sarma HD, Das T, Banerjee S, Venkatesh M, Vidyasagar PB, Mishra KP (2010) Biologic evaluation of a novel 188Re-labeled porphyrin in mice tumor model. Cancer Biother Radiopharm 25:47–54
Kinuya S, Yokoyama K, Tega H, Hiramatsu T, Konishi S, Watanabe N, Shuke N, Aburano T, Takayama T, Michigishi T, Tonami N (1999) Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts. J Cancer Res Clin Oncol 125:630–636
Acknowledgements
The authors would like to thank Mr. C. J. Liu for his help with the preparation of 188Re.
Conflicts of interest statement
We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled “Therapeutic Efficacy of 188 Re-liposome in a C26 Murine Colon Carcinoma Solid Tumor Model”.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chang, YJ., Hsu, CW., Chang, CH. et al. Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model. Invest New Drugs 31, 801–811 (2013). https://doi.org/10.1007/s10637-012-9906-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-012-9906-7